Previous 10 | Next 10 |
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financia...
Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET ® platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas. Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: ...
IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IPH45, a differentiated topoisomerase I inhibitor ADC targeting Nectin-4, which is progressing towards the clinic Regulatory News: Innate...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below. Leerin...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
2024-01-11 08:42:53 ET Summary Innate Pharma is a European biotech specializing in the development of immunotherapeutics for various cancer types. Their most advanced projects focus on engaging and activating natural killer cells, with promising results in clinical trials. The...
2024-01-04 08:15:14 ET Minim ( MINM ) +145% . Omega Therapeutics ( OMGA ) +109% signs research deals on cardiometabolic diseases. Jeffs Brands ( JFBR ) +41% . ATIF Holdings ( ATIF ) +20% . Arena Group Holdings ( ...
2024-01-04 04:25:35 ET More on Innate Pharma: Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi Seeking Alpha’s Quant Rating on Innate Pharma For further details see: FDA lifts partial clinical hold on Innate Pharma's lacutamab c...
FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ...
Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and ...
News, Short Squeeze, Breakout and More Instantly...
Innate Pharma S.A. Company Name:
IPHA Stock Symbol:
NYSE Market:
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Prec...